Evidence & access
Semaglutide vs. tirzepatide: what the head-to-head trials show
SURMOUNT-5 compared obesity doses directly. Read the results alongside STEP-1, SURMOUNT-1 and SURPASS-2, with their limits.
Updated · Editorial standards
In this brief
Tirzepatide produced greater average weight loss than semaglutide in SURMOUNT-5, a direct trial in adults with obesity without diabetes: 20.2% versus 13.7% at 72 weeks.1 That is a group result at the doses studied, not a prediction for one person or proof that every formulation sold online has the same evidence.
The obesity comparison: SURMOUNT-5
Published in 2025, SURMOUNT-5 randomized 751 participants to once-weekly tirzepatide or semaglutide. The maximum tolerated trial doses were tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg. This directly addresses obesity treatment without diabetes, unlike the older diabetes trial often used in comparisons.1
The 20.2% and 13.7% results differ by 6.5 percentage points. That is not the same as saying an individual will lose another 6.5% by switching drugs. To illustrate the arithmetic only, applying those percentages to a hypothetical 200-pound starting weight gives 40.4 and 27.4 pounds. These calculations translate the percentages; they are not expected outcomes for a particular reader.
The study was open-label, meaning participants knew which drug they received. Eli Lilly, tirzepatide's manufacturer, sponsored it. Participants also received diet and exercise counseling. These details belong beside the result because they help explain how the study was conducted and what its comparison represents.5
What STEP-1 and SURMOUNT-1 add
STEP-1 tested semaglutide 2.4 mg against placebo in adults with overweight or obesity without diabetes. At 68 weeks, mean weight change was about minus 14.9% with semaglutide and minus 2.4% with placebo, alongside lifestyle intervention.2 It established a substantial treatment effect, but did not compare semaglutide with tirzepatide.
SURMOUNT-1 tested tirzepatide against placebo in adults without diabetes over 72 weeks. Mean weight reductions were about 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg, compared with 3.1% for placebo.3 These dose-specific results answer a different question from a maximum-tolerated-dose comparison.
Do not subtract results from those two separate trials as though the participants had been randomized together. Different study populations, treatment schedules and follow-up periods can influence outcomes. SURMOUNT-5 provides the more direct evidence for the particular obesity-dose comparison it tested.
The diabetes comparison: SURPASS-2
SURPASS-2 compared tirzepatide 5, 10 and 15 mg with semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Tirzepatide produced greater reductions in blood glucose and body weight in that study.4 Its semaglutide dose and diabetes population make it different from SURMOUNT-5.
Read each trial with its question attached: STEP-1 asks about semaglutide versus placebo; SURMOUNT-1 asks about tirzepatide versus placebo; SURPASS-2 compares diabetes treatment; SURMOUNT-5 compares the studied obesity regimens without diabetes. Mixing the results loses information that matters to a treatment discussion.
What the results cannot decide for you
A trial average does not tell you which medication you will tolerate, what your insurer will cover or whether a particular dose is appropriate. Greater mean weight loss also does not answer every question about other health outcomes. Discuss your treatment goals and medical history with the prescriber rather than choosing from the largest percentage alone.
The SURMOUNT-5 comparison concerns the injected regimens and doses described above. It does not establish a head-to-head result for oral preparations, every other dose or compounded products. Compounded drugs are not FDA-approved finished products; see our brand versus compounded guide for that distinction.6
Questions for your clinician
Ask which trial population most resembles your situation, which outcomes matter beyond weight and what would prompt a change in treatment. Ask how tolerability and follow-up will be assessed. If price is a concern, explain the budget constraint so the discussion includes something you can sustain rather than only a medication name.
Our semaglutide cost guide, tirzepatide cost guide and side-effect overview cover different parts of that decision. Provider terms belong in our review index; they should not be confused with trial evidence about a drug.
This article was substantively revised to include SURMOUNT-5 and distinguish it from the older SURPASS-2 comparison. It summarizes research for a conversation with a licensed clinician, not a self-directed switch or dosing plan.
Frequently asked questions
Has tirzepatide been compared directly with semaglutide at obesity doses?
Yes. SURMOUNT-5 compared maximum tolerated trial doses of injected tirzepatide and semaglutide in adults with obesity without diabetes over 72 weeks.
How much weight loss did SURMOUNT-5 report?
Average weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks. These are trial averages, not individual predictions.
Is SURPASS-2 the same comparison?
No. SURPASS-2 studied adults with type 2 diabetes and used semaglutide 1 mg; it answers a different question from the obesity-dose SURMOUNT-5 trial.
References
- Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Weill Cornell Medicine (2025). Head-to-Head Trial Compares Weight Loss Drugs. Weill Cornell Medicine. https://news.weill.cornell.edu/news/2025/05/head-to-head-trial-compares-weight-loss-drugs
- U.S. Food and Drug Administration (2026). Compounding and the FDA: Questions and Answers. FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Beyond the scale: what GLP-1s do for your heart, kidneys, and sleep apnea
Three landmark randomized trials — SELECT, FLOW, and SURMOUNT-OSA — tested GLP-1s for cardiovascular events, kidney disease, and sleep apnea. What each found.
ReadGLP-1 insurance coverage: what's covered, what isn't, and prior authorization
How GLP-1 insurance coverage actually works — the diabetes-vs-obesity split, prior authorization, Medicare's exclusion, and how to check your own plan.
ReadGLP-1 lab costs: questions to ask before enrollment
Find out who orders, performs and bills for required tests, whether existing results are accepted, and what a self-pay estimate includes.
ReadGLP-1 weight-loss timeline: what to expect month by month
A realistic, trial-backed picture of GLP-1 weight loss — why month one is slow, when results accelerate, and where they typically level off.
ReadOral GLP-1 pills explained: orforglipron and oral semaglutide
Foundayo and the Wegovy pill are both FDA-approved now. What each oral GLP-1 is, what the trials show, and how a daily pill compares with the shots.
ReadPepti review: GLP-1 pricing and program limits
Pepti’s dated $109 semaglutide offer leaves dose-pricing questions unresolved. Compare the recorded terms, pharmacy disclosures and evidence limitations.
Read